Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.

Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.

Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.

Abstract: A minimally invasive treatment of benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. A method includes introducing a composition into the prostate to achieve a sustained release of the cytostatic or cytotoxic drug over a period of between about 14 days and 12 months.

Abstract: A capsule device with thermally-stable specific gravity control is disclosed. The capsule device comprises a capsule unit adapted to be swallowable by a human subject and an inflatable balloon comprising a thermally-stable effervescent formulation inside the inflatable balloon, where the thermally-stable effervescent formulation has a particular particle size between a first mesh size and a second mesh size, and the inflatable balloon is attached to the capsule unit. After the capsule unit with the inflatable balloon attached is swallowed, the inflatable balloon starts to inflate so as to lower specific gravity of a combination of the capsule unit and the inflatable balloon when the inflatable balloon is exposed to body fluid and the body fluid gets in touch with the thermally-stable effervescent formulation inside the inflatable balloon.

Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.

Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.

Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.

Abstract: Bioabsorbable scaffolds having high crush recoverability, high fracture resistance, and reduced or no recoil due to self expanding properties at physiological conditions are disclosed. The scaffolds are made from a random copolymer PLLA and a rubbery polymer such as polycaprolactone.

Abstract: A stent made from a material comprising a polymer is disclosed. The stent has a pre-crimp diameter and a wall thickness such that a ratio of the pre-crimp diameter to the wall thickness is between 30 and 60. The stent has a pattern of interconnected elements. The interconnected elements including a plurality of rings connected by links, wherein each ring includes struts and crowns, and the struts are configured to fold at the crowns when the stent is crimped to the balloon.

Abstract: Bioabsorbable scaffolds having high crush recoverability, high fracture resistance, and reduced or no recoil due to self expanding properties at physiological conditions are disclosed. The scaffolds are made from a random copolymer of PLLA and a rubbery polymer such as polycaprolactone.

Abstract: A medical device includes a polymer stent (or scaffold) crimped to a catheter balloon. The stent, after being expanded from a crimped state by the balloon, provides a crush recovery of about 90% of its expanded diameter after being pinched or crushed by an amount equal to about 50% of the expanded diameter. The stent has a pattern including a W-shaped or W-V shaped closed cell and links connecting the closed cells.

Abstract: The present invention discloses a capsule device with specific gravity control. The capsule device comprises a capsule unit adapted to be ingested by a human subject, and an inflatable balloon comprising an effervescent formulation inside the inflatable balloon. The effervescent formulation comprises sodium carbonate, potassium bicarbonate or both with excess citric acid and the inflatable balloon is attached to the capsule unit. After the capsule unit with the inflatable balloon attached is swallowed, the inflatable balloon starts to inflate so as to lower the specific gravity, of the combined device comprising a combination of the capsule unit and the inflatable balloon, when the inflatable balloon is exposed to body liquid and the body liquid gets in touch with the effervescent formulation inside the inflatable balloon.

Abstract: A minimally invasive treatment of benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. A method includes introducing a composition into the prostate to achieve a sustained release of the cytostatic or cytotoxic drug over a period of between about 14 days and 12 months.

Abstract: A medical device includes a polymer scaffold crimped to a catheter having an expansion balloon. The scaffold has a structure that produces a low late lumen loss when implanted within a peripheral vessel and also exhibits a high axial fatigue life. In a preferred embodiment the scaffold forms ring structures interconnected by links, where a ring has 12 crowns and at most two links connecting adjacent rings.

Abstract: The present invention discloses a capsule endoscope with specific gravity control. The capsule endoscope comprises a housing to enclose various components, an inflatable device attached to a first longitudinal end of the capsule unit and an enteric coated shell attached to the first longitudinal end of the capsule unit to enclose the inflatable device between the enteric coated shell and the capsule unit. The various components include a camera sub-system for capturing image frames. The inflatable device comprises an inflatable membrane and an effervescent formulation inside the inflatable membrane. The enteric coated shell fits tightly onto the first longitudinal end of the capsule unit to prevent body liquid from leaking into a space between the enteric coated shell and the capsule unit when the capsule unit travels in human gastrointestinal tract after being swallowed.

Abstract: The present invention discloses a capsule endoscope with specific gravity control. The capsule endoscope comprises a housing to enclose various components, an inflatable device attached to a first longitudinal end of the capsule unit and an enteric coated shell attached to the first longitudinal end of the capsule unit to enclose the inflatable device between the enteric coated shell and the capsule unit. The various components include a camera sub-system for capturing image frames. The inflatable device comprises an inflatable membrane and an effervescent formulation inside the inflatable membrane. The enteric coated shell fits tightly onto the first longitudinal end of the capsule unit to prevent body liquid from leaking into a space between the enteric coated shell and the capsule unit when the capsule unit travels in human gastrointestinal tract after being swallowed.

Abstract: The present invention discloses a capsule endoscope with specific gravity control. The capsule endoscope comprises a housing to enclose various components, an inflatable device attached to a first longitudinal end of the capsule unit and an enteric coated shell attached to the first longitudinal end of the capsule unit to enclose the inflatable device between the enteric coated shell and the capsule unit. The various components include a camera sub-system for capturing image frames. The inflatable device comprises an inflatable membrane and an effervescent formulation inside the inflatable membrane. The enteric coated shell fits tightly onto the first longitudinal end of the capsule unit to prevent body liquid from leaking into a space between the enteric coated shell and the capsule unit when the capsule unit travels in human gastrointestinal tract after being swallowed.

Abstract: Bioabsorbable scaffolds having high crush recoverability, high fracture resistance, and reduced or no recoil due to self expanding properties at physiological conditions are disclosed. The scaffolds are made from a random copolymer of PLLA and a rubbery polymer such as polycaprolactone.

Abstract: An endoscopy capsule having an image collecting capacity includes a deformable member configured to inflate when exposed to body liquid. The deformable member includes an effervescent material. When the effervescent reacts with water the resulting Carbon-Dioxide gas reduces the specific gravity of the endoscopy capsule. The capsule is contained within a shell or dome when swallowed. The shell or dome is configured dissolve in either a low or high pH environment.